Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain
March 18, 2025 08:45 ET
|
Dogwood Therapeutics, Inc.
ATLANTA, March 18, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (“Dogwood” or the “Company”), a development-stage biopharmaceutical company focused on advancing first-in-class,...
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
March 04, 2025 08:00 ET
|
Indaptus Therapeutics
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral...
Penn Highlands Healthcare Screening Program Successfully Detects Early Lung Cancer
February 10, 2025 09:36 ET
|
Penn Highlands Healthcare
DuBois, Pennsylvania, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Lung cancer is a source of more cancer deaths in the U.S. than breast, colon and prostate cancer combined. People diagnosed with lung cancer...
CERo Therapeutics, Inc. Successfully Completes IND-Enabling Toxicology Studies for Lead Compound CER-1236
June 06, 2024 08:00 ET
|
CERo Therapeutics Holdings, Inc.
Company continuing IND-enabling activities in preparation for submission of Investigational New Drug Application to FDA SOUTH SAN FRANCISCO, Calif., June 06, 2024 (GLOBE NEWSWIRE) -- CERo...
Telomir Pharmaceuticals, Inc. Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
May 16, 2024 09:30 ET
|
FMW Media Works Corp
Telomir Pharmaceuticals, Inc. (NASDAQ: TELO)Signs Media Deal with New to The Street for Network Interview Broadcasts, Billboards, and TV Commercial Support
Medicenna Announces First Patient Dosed in ABILITY-1 Study of MDNA11 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors
February 13, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
The ABILITY-1 Study is evaluating MDNA11, a highly selective long-acting IL-2 Superkine, in combination with KEYTRUDA® (pembrolizumab) for treatment of patients with advanced solid tumorsMDNA11...
New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10:30 PM PT
December 08, 2023 09:46 ET
|
FMW Media Works Corp
New to The Street TV Features Five Corporate Guest Interviews, Episode 537 Airs on the FOX Business Network, Monday, December 11, 2023, at 10;30 PM PT
New to The Street TV Announces Its Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Tonight, Thursday, December 7, 2023, at 9:30 PM PT
December 07, 2023 09:20 ET
|
FMW Media Works Corp
New to The Street TV Announces Episode 536 Lineup, Five Corporate Guest Interviews, Broadcasted as Sponsored Program on Bloomberg TV, Dec. 7. 9:30 PM PT
Investigator Sponsor of HCW Biologics’ Phase 1 Clinical Trial Presented Human Data Readout and Anti-Cancer Mechanism of Action of HCW9218 at 38th SITC Annual Meeting
November 08, 2023 07:30 ET
|
HCW Biologics, Inc
Preliminary data readout from a Phase 1 study to evaluate HCW9218, the lead drug candidate of HCW Biologics, in solid tumors.
New to The Street Announces Six Business Interviews on its 524th Show, Airing on the Fox Business Network, Monday, October 23, 2023, at 10:30 PM PT
October 20, 2023 10:43 ET
|
FMW Media Works Corp
FMW Media's New to The Street, a national TV show, announces episode 524th airing on the Fox Business Network, Monday, October 23, 2023, at 10:30 PM PT